Advertisement
MDXG vs NTLA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDXG is a Hold and NTLA is a Hold.
MDXG's RSI Indicator recovers from oversold territory
The RSI Oscillator for MDXG moved out of oversold territory on October 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 31 of the 35 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 52 cases where MDXG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDXG advanced for three days, in 192 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
MDXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDXG as a result. In 79 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for MDXG turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 26 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
MDXG moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MDXG crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for MDXG entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MDXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.621) is normal, around the industry mean (3.162). MDXG has a moderately high P/E Ratio (77.600) as compared to the industry average of (-1.064). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (1.985) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for NTLA turns positive, indicating new upward trend
NTLA saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 79 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for NTLA just turned positive on October 28, 2026. Looking at past instances where NTLA's MACD turned positive, the stock continued to rise in 37 of 46 cases over the following month. The odds of a continued upward trend are 80%.
NTLA moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +18.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in 202 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 103 of 128 cases where NTLA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NTLA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.401) is normal, around the industry mean (3.162). P/E Ratio (-3.734) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MDXG | NTLA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 88 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | 47 | |
P/E GROWTH RATING 1..100 | 4 | 63 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTLA's Valuation (37) in the Biotechnology industry is somewhat better than the same rating for MDXG (95). This means that NTLA’s stock grew somewhat faster than MDXG’s over the last 12 months.
NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MDXG (100). This means that NTLA’s stock grew similarly to MDXG’s over the last 12 months.
MDXG's SMR Rating (88) in the Biotechnology industry is in the same range as NTLA (98). This means that MDXG’s stock grew similarly to NTLA’s over the last 12 months.
NTLA's Price Growth Rating (47) in the Biotechnology industry is in the same range as MDXG (63). This means that NTLA’s stock grew similarly to MDXG’s over the last 12 months.
MDXG's P/E Growth Rating (4) in the Biotechnology industry is somewhat better than the same rating for NTLA (63). This means that MDXG’s stock grew somewhat faster than NTLA’s over the last 12 months.
| MDXG | NTLA | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 89% | N/A |
| Stochastic ODDS (%) | 4 days ago 71% | 4 days ago 90% |
| Momentum ODDS (%) | 4 days ago 75% | 4 days ago 84% |
| MACD ODDS (%) | 7 days ago 70% | 4 days ago 80% |
| TrendWeek ODDS (%) | 4 days ago 78% | 4 days ago 78% |
| TrendMonth ODDS (%) | 4 days ago 81% | 4 days ago 78% |
| Advances ODDS (%) | 5 days ago 73% | 6 days ago 78% |
| Declines ODDS (%) | 8 days ago 80% | 4 days ago 88% |
| BollingerBands ODDS (%) | 4 days ago 75% | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 81% | 4 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDXG’s FA Score shows that 1 FA rating(s) are green while NTLA’s FA Score has 0 green FA rating(s).
- MDXG’s FA Score: 1 green, 4 red.
- NTLA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDXG’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).
- MDXG’s TA Score: 4 bullish, 6 bearish.
- NTLA’s TA Score: 5 bullish, 4 bearish.
Price Growth
MDXG (@Biotechnology) experienced а -0.77% price change this week, while NTLA (@Biotechnology) price change was +11.24% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.43%. For the same industry, the average monthly price growth was -12.73%, and the average quarterly price growth was -19.68%.
Reported Earning Dates
MDXG is expected to report earnings on Mar 03, 2027.
NTLA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-0.43% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MDXG and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To MDXG | 1D Price Change % | ||
|---|---|---|---|---|
| MDXG | 100% | -2.27% | ||
| AXON - MDXG | 47% Loosely correlated | -2.35% | ||
| VCYT - MDXG | 42% Loosely correlated | -4.14% | ||
| ARRY - MDXG | 39% Loosely correlated | -4.78% | ||
| INM - MDXG | 38% Loosely correlated | -2.47% | ||
| TAOX - MDXG | 34% Loosely correlated | -10.44% | ||
More | ||||